非瓣膜性心房颤动患者内皮和血小板功能及β受体阻滞剂干预的临床意义

目的 探讨非瓣膜性心房颤动(房颤)与内皮细胞功能及血小板功能的关系,观察β受体阻滞剂治疗对房颤患者内皮功能及血小板功能的影响.方法 非瓣膜性持续性房颤患者(房颤组)25例,窦性心律组(窦律组)35例,通过竞争性酶联免疫(ELASA)分析定量测定两组血清血管性血友病因子(von Willebrand Factor,vWF)和可溶性P选择素水平,及房颤组β受体阻滞剂治疗后上述指标的变化.结果 房颤组血清vWF水平(1945.2±111.3)g/L高于窦律组(1862.3±101.6)g/L,差异有统计学意义(P＜0.05).房颤组患者服用β受体阻滞剂(阿替洛尔)后,血清vWF水平下降至(1758.3±152.4)g/L,与服药前比较差异有统计学意义(P＜0.01).血清可溶性P选择素水平房颤组与窦律组[分别为(24.32±9.21)g/L与(24.68±11.70)g/L]比较,差异无统计学意义(P＞0.05),服用β受体阻滞剂后血清可溶性P选择素水平下降至(21.05±8.94)g/L,但与服药前相比差异无统计学意义(P＞0.05).vWF与可溶性P选择素无相关性(Pearson相关系数为-0.008,P＞0.05).结论 房颤患者血清vWF水平较窦性心律者升高,提示存在心血管内皮损伤.服用阿替洛尔后,房颤患者血清vWF水平下降,提示阿替洛尔用于房颤患者除能有效控制心室率外,还可能具有内皮保护功能.

Abstract：

Objective To examine the serum von Willebrand factor (vWF) and soluble Pselectin levels in patients with non-valvular atrial fibrillation (NVAF), and to observe the influence of beta-blocker treatment on endothelial function and platelet activation in NVAF patients. Methods The 25 subjects, 17 males and 8 females, with persistent NVAF and left ventricular ejection fraction (LVEF)≥50%, were enrolled in NVAF group. Those with myocardial infarction, cardiomyopathy or hyperthyroidism were excluded. Another 35 subjects with sinus rhythm were as control (age,gender and LVEF matched with NVAF group, and with similar cardiovascular diseases). Serum vWF and soluble P-selectin levels were tested by enzyme-linked immunosorbent assay. Results The serum vWF level was significantly higher in NVAF group than in control group [(1945.2±111.3) g/L vs. (1862.3±101.6) g/L, P＜0.05]. However, there was no significant difference in serum soluble P-selectin level between NVAF group and control group [(24.32±9.21) g/L vs. (24.68±11.70) g/L, P＞0. 05]. After administration of beta-blocker, a down-regulation was found in serum vWF level [(1758. 3±152. 4) g/L, P＜0. 01], but not in soluble P-selectin level [(21.05±8. 94) g/L, P＞0. 05]. There was no relationship between serum level of vWF and soluble P-selectin (r=-0.008,P＞0. 05). Conclusions High serum level of vWF is found in patients with persistent NVAF as compared with control, indicating endothelial damage/dysfunction in those patients. After administration of beta-blocker, serum level of vWF drops dramatically in NVAF patients, indicating possible endothelial function protection of beta-blocker.

Endothelial function and platelet activation in patients with non-valvular atrial fibrillation and the influence of beta-blocker on them

Objective To examine the serum von Willebrand factor (vWF) and soluble Pselectin levels in patients with non-valvular atrial fibrillation (NVAF), and to observe the influence of beta-blocker treatment on endothelial function and platelet activation in NVAF patients. Methods The 25 subjects, 17 males and 8 females, with persistent NVAF and left ventricular ejection fraction (LVEF)≥50%, were enrolled in NVAF group. Those with myocardial infarction, cardiomyopathy or hyperthyroidism were excluded. Another 35 subjects with sinus rhythm were as control (age,gender and LVEF matched with NVAF group, and with similar cardiovascular diseases). Serum vWF and soluble P-selectin levels were tested by enzyme-linked immunosorbent assay. Results The serum vWF level was significantly higher in NVAF group than in control group [(1945.2±111.3) g/L vs. (1862.3±101.6) g/L, P＜0.05]. However, there was no significant difference in serum soluble P-selectin level between NVAF group and control group [(24.32±9.21) g/L vs. (24.68±11.70) g/L, P＞0. 05]. After administration of beta-blocker, a down-regulation was found in serum vWF level [(1758. 3±152. 4) g/L, P＜0. 01], but not in soluble P-selectin level [(21.05±8. 94) g/L, P＞0. 05]. There was no relationship between serum level of vWF and soluble P-selectin (r=-0.008,P＞0. 05). Conclusions High serum level of vWF is found in patients with persistent NVAF as compared with control, indicating endothelial damage/dysfunction in those patients. After administration of beta-blocker, serum level of vWF drops dramatically in NVAF patients, indicating possible endothelial function protection of beta-blocker.